Clinical trial of paclitaxel injection combined with nedaplatin injection in the treatment of patients with metastatic cervical cancer
10.13699/j.cnki.1001-6821.2017.13.006
- VernacularTitle:紫杉醇注射液联合奈达铂注射剂治疗晚期复发转移性宫颈癌的临床研究
- Author:
Dong-Li ZHANG
1
;
Yan-Yun LI
;
Jun TIAN
;
Hong-Xia ZHANG
;
She-Lian WANG
;
Gui-Xia SUN
Author Information
1. 河南大学淮河医院妇产科
- Keywords:
paclitaxel injection;
nedaplatin injection;
cervical cancer;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(13):1188-1190
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of paclitaxel injection combined with nedaplatin injection in the treatment of advanced recurrent metastatic cervical cancer.Methods Forty-five patients with advanced recurrent metastatic cervical cancer were given intravenous infusion of 150 mg · m-2 paclitaxel,day 1 + 80 mg · m-2 nedaplatin,day 1.The curative effect,adverse drug reactions and prognosis were observed.Results After treatment,complete remission was 3 cases (6.67％),partial response was 21 cases (46.67％),stable disease was 10 cases (22.22％),progress disease was 11 cases (24.44％),objective response rate was 53.33％ (24/45 cases).The clinical efficacy of time since the last chemotherapy (＞ 12 months or ≤ 12 months) were 20.00％ (3/15 cases) and 80.95％ (17/21 cases) with significant difference (P ＜ 0.05).Median overall survival time was 13.90 months with 42 patients died.Cox single regression showed that there were no significant differences between patients in terms of chemotherapy or not,and median overall survival rate since the last chemotherapy (P ＞0.05).The adverse drug reactions were based on bone marrow suppression,gastrointestinal reactions,fatigue and peripheral nerve sensory abnormalities.Conclusion Paclitaxel injection combined with nedaplatin injection has a definitive clinical efficacy and safety for the treatment of metastatic cervical cancer with good prognosis.
